Pfizer Clinical Trials for Metastatic Prostate Cancer are Now Enrolling

About the Study

The study will determine whether the study medicine mevrometostat can delay or stop the growth of metastatic prostate cancer. Mevrometostat is thought to work by blocking the abnormal EZH2 activity in cells, which may help prevent or delay hormone therapy resistance and cancer growth and progression.

What the Study Involves

If you choose to enroll, you will need to make visits to the study site for study treatment and follow up visits. The activities that take place during the study visits will also vary, but may include blood tests, an EKG (electrocardiogram), and medical imaging.

All study participants will receive standard-of-care treatment either alone or along with the study medication, that will be taken orally twice-a-day. Standard-of-care treatments are established treatments that are widely accepted by medical professionals and may vary depending on the location of the patient.

Your study doctor will provide you with more information about the clinical trial, including study visit activities, during the informed consent process. If one of the MEVPRO clinical trials is a good fit for you and you decide to take part, it’s important to remember that joining is your choice, and you are free to stop being in a clinical trial at any time for any reason.

Study Locations

To see study site locations, please click here MEVPRO Clinical Trials.

• Diagnosis of metastatic prostate cancer
• Males 18 years or older
• Each MEVPRO clinical trial will have its own unique requirements for who may participate. To learn more about the requirements for a study that is actively recruiting, visit the webpage here: MEVPRO Clinical Trials

• Do not have a diagnosis of metastatic prostate cancer
• Females
• Under the age of 18 years old